ClinicalTrials.gg
Active, not recruitingNCT06050577Updated Oct 5, 2026

The Effect of Oral Semaglutide on Bone Turnover in Patients With T2D: a Randomized Placebo-controlled Clinical Trial

A Phase 2 interventional study of oral Semaglutide/Rybelsus and Placebo in Type 2 Diabetes and Osteopenia, sponsored by Odense University Hospital. Active, not recruiting at 1 site in Denmark. Open to participants aged 50 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-10-05.

Sponsored by Odense University Hospital · Phase 2, Interventional, and Treatment

How we know · 4 judgments

Updated Oct 5, 2026Eligibility revisedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
64
Allocation
Randomized
Ages
50 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 163 studies testing semaglutide in Diabetes Mellitus, Type 2 — 35 open to participants now, 45 under way, 9 of them phase 3. Semaglutide · Diabetes Mellitus, Type 2.

Planned enrollment
109th of 163
64 · median 104
Started
2024
with 17 others
Phase 2
10 of 163
1 open now
Primary completion
2027-01
later than 23 of 44 live
Registered
122nd of 163
by date

Among the 163 studies testing semaglutide in Diabetes Mellitus, Type 2, this one is the 109th largest by planned enrollment, is one of 18 that started in 2024, is one of 10 in phase 2, reaches primary completion later than 23 of the 44 other live ones, and was the 122nd registered.

Diabetes Mellitus, Type 2

10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

35 of the 163 studies testing semaglutide in Diabetes Mellitus, Type 2 are open now, in 12 countries. Recruiting first, the newest first:

30 more — sign in →

By country, each count listing its studies:

All 35 open studies →

About semaglutide

Semaglutide: first FDA approval 2017 (OZEMPIC), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 50 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 163 studies testing semaglutide in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

The hypothesis for this study is that oral Semaglutide, a GLP-1Ra, has a positive effect on the balance between build-up and degradation as well as the strength of the bones in men and women aged 50-85 years with type 2 diabetes and an increased risk of bone fractures. Treatment involves once daily oral GLP-1Ra semaglutide or matching placebo for 52 weeks. The effect will be measured by bone markers in blood samples, bone scans, bone tissue and bone marrow tests (bone marrow aspiration and biopsy), physical activity assessed by a questionnaire, and direct bone strength measured by microindentation at the start and end of the study.

03

Conditions studied

  • Type 2 Diabetes
  • Osteopenia
04

Who can participate

The criteria were revised on the registry on Oct 5, 2026. See what changed

Ages eligible
50 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Type 2 diabetes and glycosylated () of 48-91 mmol/mol (6.5-10.5%) and
  • T-score \<+1 in hip or lower back, assessed by DXA scan and / or
  • Low-energy fracture within the last 3 years

Exclusion criteria

Exclusion criteria

  • T-score \<-2.5 in hip or lower back, assessed by DXA scan, although these individuals may be included if they are not candidates for conventional osteoporosis therapy, e.g., due to allergies and renal impairment, or if they prefer to participate in the trial.
  • Type 1 diabetes mellitus
  • Severe NPDR (non-proliferative diabetic retinopathy) or PDR (proliferative diabetic retinopathy) assessed within the last year. If a recent assessment is unavailable, a new retinal photo test will be performed.
  • Congestive heart failure ( Class IV)
  • Primary hyperparathyroidism
  • Vitamin D deficiency (\<25 nM) (re-test after substitution acceptable)
  • Known disorders affecting bone metabolism, e.g., uncontrolled thyrotoxicosis, severe renal impairment ( \<30) or liver dysfunction (baseline phosphatase higher than twice upper limit (105 U/L)), rheumatism, celiac disease, hypogonadism, severe , hypopituitarism, Cushing's disease
  • concomitant diseases or disorders (e.g., cancer) or clinically significant abnormal values in laboratory screening tests, including increased Choriogonadotropin (hCG) in women.
  • History of gastrointestinal surgery (except uncomplicated surgical procedures such as hernia surgery and appendectomy)
  • Antiresorptive or bone anabolic drugs for the last 12 months
  • Use of anabolic steroids in the previous year
  • Use of GLP-1Ras within 90 days
  • Stable therapy with DPP4 inhibitors (unless the patient is willing to discontinue the treatment)
  • History of pancreatitis
  • Allergy or to the active substance or to any of the ingredients
  • Inability to give
  • Previous bariatric surgery
  • \<20 kg/m2 or BMI>37 kg/m2
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
64 participants (estimated)

Study arms

  • Experimental
    oral Semaglutide/Rybelsus

    oral Semaglutide 7-14 mg (or highest tolerated dose) once daily for 52 weeks (incl. titration)

    Drug: oral Semaglutide/Rybelsus

  • Placebo comparator
    oral Placebo

    oral Placebo 7-14 mg (or highest tolerated dose) once daily for 52 weeks (incl. titration)

    Drug: Placebo

Interventions

  • Drugoral Semaglutide/Rybelsus

    Drug page: SemaglutideStudies of SemaglutideSemaglutide pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Weeks 1-4: 3 mg of oral semaglutide once daily. Weeks 5-52: 7 mg of semaglutide once daily as maintenance dose. Dose may be increased to 14 mg of semaglutide once daily as maintenance dose after 2 months if glucose levels are out of range.

  • DrugPlacebo

    Weeks 1-4: 3 mg of oral placebo once daily. Weeks 5-52: 7 mg of placebo once daily as maintenance dose. Dose may be increased to 14 mg of placebo once daily as maintenance dose after 2 months if glucose levels are out of range.

06

What researchers measure

Primary outcomes

  1. Procollagen type 1 N-terminal propeptide (P1NP)

    Percentage changes in bone formation marker P1NP from baseline and after 12 months

    Time frame: Baseline and 52 weeks

Secondary outcomes

  1. Collagen 1 cross link C-terminal telopeptide (CTX)

    Changes in bone resorption marker CTX from baseline and after 12 months

    Time frame: Baseline and 52 weeks

  2. Osteocalcin

    Changes in bone formation marker osteocalcin from baseline and after 12 months

    Time frame: Baseline and 52 weeks

  3. Bone specific alkaline phosphatase (BALP)

    Changes in bone formation marker BALP from baseline and after 12 months

    Time frame: Baseline and 52 weeks

  4. Bone mineral density (BMD)

    Changes in BMD (total hip, femoral neck and lumbar spine (L1-4)) assessed by DXA scans from baseline and after 12 months

    Time frame: Baseline and 52 weeks

  5. Estimated bone strength

    Changes in estimated bone strength assessed by finite elemental analysis (HR-pQCT scan) from baseline and after 12 months

    Time frame: Baseline and 52 weeks

  6. Total volumetric BMD

    Changes in total volumetric BMD (mg/cm\^3) assessed by HR-pQCT scan of distal tibia and radius

    Time frame: Baseline and 52 weeks

  7. Trabecular volumetric BMD

    Changes in trabecular volumetric BMD (mg/cm\^3) assessed by HR-pQCT scan of distal tibia and radius

    Time frame: Baseline and 52 weeks

  8. Cortical volumetric BMD

    Changes in cortical volumetric BMD (mg/cm\^3) assessed by HR-pQCT scan of distal tibia and radius

    Time frame: Baseline and 52 weeks

  9. Bone volume

    Changes in trabecular bone volume pr total volume (BV/TV) assessed by HR-pQCT scan of distal tibia and radius

    Time frame: Baseline and 52 weeks

  10. Trabecular thickness

    Changes in trabecular thickness (mm) assessed by HR-pQCT scan of distal tibia and radius

    Time frame: Baseline and 52 weeks

  11. Cortical thickness

    Changes in cortical thickness (mm) assessed by HR-pQCT scan of distal tibia and radius

    Time frame: Baseline and 52 weeks

  12. Cortical porosity

    Changes in cortical porosity assessed by HR-pQCT scan of tibia and radius

    Time frame: Baseline and 52 weeks

  13. Bone formation rate

    Changes in bone formation rate (BRF/BS, µm\^3/µm\^2 per day), the volume of mineralized bone made per unit surface of bone per year, based on dynamic histomorphometry of bone tissue

    Time frame: 52 weeks

  14. Fat tissue distribution

    Change in fat tissue distribution, assessed by DXA

    Time frame: Baseline and 52 weeks

  15. Lean tissue distribution

    Change in lean tissue distribution, assessed by DXA

    Time frame: Baseline and 52 weeks

  16. Glycosylated haemoglobin (HbA1C)

    Change in HbA1c from baseline and after 12 months

    Time frame: Baseline and 52 weeks

  17. Physical activity

    Change in physical activity based on analysis of International Physical Activity Questionnaire Short Form (IPAQ-SF) from baseline and after 12 months

    Time frame: Baseline and 52 weeks

  18. Body mass index (BMI)

    Change in BMI from baseline and after 12 months

    Time frame: Baseline and 52 weeks

Other outcomes

  1. Osteogenic potential

    Change in osteogenic potential, i.e., ability to form new bone, assessed using spatial transcriptomics and single-cell RNA sequencing.

    Time frame: 52 weeks

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2024 (actual). Primary completion is estimated for Jan 2027, 31 months after the start.

Of 99 non-industry phase 2 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 50. This study's planned 31 months is close to that.

Counting every sponsor, half of 293 studies reached it within 15 months; a quarter within 11 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 8, 2023
First posted
Sep 22, 2023
StartActual
Jun 7, 2024
Primary completionEst.
Jan 15, 2027
CompletionEst.
Mar 15, 2027
Last update
Oct 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Eligibility
1 inclusion criterion edited
What changed in the criteria
Inclusion criteria
  • EditedT-score <-+1 in hip or lower back, assessed by DXA scan and / or
Oct 5, 2026
Show all 1 update
  1. Oct 5, 2026
    Eligibility 1 inclusion criterion edited
    What changed in the criteria
    Inclusion criteria
    • EditedT-score <-+1 in hip or lower back, assessed by DXA scan and / or
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06050577
Responsible party
Sponsor
First posted
Sep 22, 2023
Start date
Jun 7, 2024
Primary completion
Jan 15, 2027 (estimated)
Completion
Mar 15, 2027 (estimated)
Last update
Oct 5, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Semaglutide

Start the discussion